Metformin Ingen Pharma (Metformin Hydrochloride)

Metformin Hydrochloride lowers blood glucose by inhibiting hepatic glucose production, decreasing intestinal glucose absorption, and enhancing peripheral insulin sensitivity through activation of AMP‑activated protein kinase (AMPK). These actions collectively reduce fasting and post‑prandial glucose levels without stimulating insulin release.

The appropriate dose of Metformin Ingen Pharma is determined by the prescribing healthcare professional based on the individual’s medical condition, renal function, and response to therapy. Dosage adjustments are made according to clinical guidelines and patient tolerance.

Metformin may be used during pregnancy when the potential benefits outweigh the risks, such as in gestational diabetes, but it should only be taken under medical supervision. Limited data are available for breastfeeding; a prescriber will evaluate safety for mother and infant before recommending use.

To order Metformin Ingen Pharma, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin is often preferred as first‑line therapy for type 2 diabetes because it improves insulin sensitivity without causing weight gain and has a low risk of hypoglycaemia. Compared with sulfonylureas or insulin, it does not stimulate insulin release, making it safer in many patients.

Metformin Ingen Pharma should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Metformin Ingen Pharma is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water and should be taken as directed by the prescribing clinician.

The most serious risk of Metformin is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, or after exposure to iodinated contrast media. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformin Ingen Pharma is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and in those who have received iodinated contrast agents without appropriate discontinuation of the drug.